Posted by Michael Wonder on 14 Jul 2021
PHARMAC has for decades refused to fund Synagis drug that could save vulnerable babies from RSV
14 July 2021 - Newshub can reveal after two decades of refusing to fund a drug that could halve the hospitalisations of vulnerable babies with respiratory illness, RSV, PHARMAC is now urgently considering a fix.
Doctors have been fighting to make the drug accessible and one family who nearly lost their child to the virus has told Newshub about their devastation after learning that PHARMAC had blocked it.
